PartnershipApr 24, 2026, 08:16 AM
Humacyte Regains Worldwide Rights for Vessel Product
AI Summary
Humacyte, Inc. amended its distribution agreement with Fresenius Medical Care Holdings, Inc., granting Humacyte sole worldwide rights to develop and commercialize its 6mm acellular tissue engineered vessel. This amendment reverses Fresenius's previous ex-U.S. distribution rights. Humacyte will now pay Fresenius low-single-digit royalties on ex-U.S. net sales after a two-year royalty-free period per country, while existing U.S. royalty obligations (mid-single to low double digits) remain. Fresenius continues its obligation to adopt the product as a standard of care in hemodialysis patients.
Key Highlights
- Humacyte regained sole worldwide rights for its 6mm acellular tissue engineered vessel.
- Will pay Fresenius low-single-digit royalties on ex-U.S. net sales.
- Includes a two-year royalty-free period for ex-U.S. sales post-launch.
- Continues to pay mid-single to low double-digit royalties on U.S. net sales.